Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up – Time to Buy?

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $8.91, but opened at $9.47. Theravance Biopharma shares last traded at $10.24, with a volume of 55,277 shares changing hands.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on TBPH shares. Leerink Partnrs lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. TD Cowen decreased their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Leerink Partners lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a research note on Monday, September 16th. Finally, StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Stock Performance

The company has a market capitalization of $481.39 million, a PE ratio of -9.92 and a beta of 0.25. The business has a fifty day moving average price of $8.32 and a 200 day moving average price of $8.68.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The business had revenue of $16.87 million for the quarter, compared to analyst estimates of $16.11 million. During the same period last year, the firm earned ($0.17) earnings per share. Research analysts forecast that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

Institutional Trading of Theravance Biopharma

Several large investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP purchased a new stake in shares of Theravance Biopharma in the third quarter worth about $60,000. China Universal Asset Management Co. Ltd. boosted its holdings in Theravance Biopharma by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 3,696 shares during the period. Hsbc Holdings PLC acquired a new position in shares of Theravance Biopharma during the second quarter worth $108,000. Ballentine Partners LLC acquired a new stake in shares of Theravance Biopharma during the third quarter valued at about $104,000. Finally, XTX Topco Ltd purchased a new position in Theravance Biopharma in the second quarter valued at about $129,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.